IP Library Granted Patent US 8,080,243
Granted Patent B2
US 8,080,243 · App. 12/558,312 · Granted Dec 20, 2011

Isolated antibody which specifically binds to PCSK9

Assignees: Rinat Neuroscience Corp.; Pfizer Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,080,243
App. No.
12/558,312
Granted
Dec 20, 2011
Kind
B2
Abstract

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Claims (3)

1. An isolated antibody which specifically binds to PCSK9 and comprises a heavy chain variable region (VH) complementary determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:8, 59, or 60, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:9 or 61, a VH CDR3 having the amino acid sequence shown in SEQ ID NO:10, a light chain variable region (VL) CDR1 having the amino acid sequence shown in SEQ ID NO:11, a VL CDR2 having the amino acid sequence shown in SEQ ID NO:12, and a VL CDR3 having the amino acid sequence shown in SEQ ID NO:13.

2. An isolated antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises the amino acid sequence of SEQ ID NO: 54 and the VL region comprises the amino acid sequence of SEQ ID NO: 53.

3. A humanized antibody comprising a light chain having the amino acid sequence of SEQ ID NO:14 and a heavy chain having the amino acid sequence of SEQ ID NO:15, with or without the C-terminal lysine of the amino acid sequence of SEQ ID NO: 15.

Assignments (1)
CHANGE OF ADDRESS FOR ASSIGNEE Recorded Mar 31, 2023
From: PFIZER INC./RINAT NEUROSCIENCE CORP.
To: PFIZER INC./RINAT NEUROSCIENCE CORP.
Reel/Frame 063874/0250 →
Continuity (4)
Provisional Application 61235643 · Aug 20, 2009
Provisional Application 61232161 · Aug 7, 2009
Provisional Application 61096716 · Sep 12, 2008
Related Publication 20100068199A1 · Mar 18, 2010